Targeting the liver to deliver a first-in-class NASH therapy
Seal Rock Therapeutics is a clinical stage company developing first-in-class treatments for inflammatory and fibrotic diseases with no available therapies. Our discovery and development efforts are focused on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that when activated under a variety of stressful disease conditions can drive severe pathological outcomes including fibrosis and inflammation. The company’s lead clinical indication is non-alcoholic steatohepatitis (NASH), while its expanding R&D pipeline offers additional compelling high unmet need disease opportunities, including alcoholic hepatitis (AH), chronic kidney disease, heart failure and Parkinson’s disease
NASH (nonalcoholic steatohepatitis) is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases in man. NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.
SRT-015 is an internally developed, next-generation ASK1 inhibitor. It has been optimized to overcome safety liabilities of first-generation ASK1 inhibitors that led to subtherapeutic dosing and subsequent lack of efficacy. It has an excellent preclinical safety and efficacy profile and is currently in clinical development.
Seal Rock’s founders and management have held scientific and leadership roles in public and private biotech and pharma companies and have been involved in the discovery and development of numerous FDA-approved drugs. Seal Rock's scientific advisers are internationally recognized experts in NASH.